SG11202002636PA - T cell receptors recognizing mutated p53 - Google Patents
T cell receptors recognizing mutated p53Info
- Publication number
- SG11202002636PA SG11202002636PA SG11202002636PA SG11202002636PA SG11202002636PA SG 11202002636P A SG11202002636P A SG 11202002636PA SG 11202002636P A SG11202002636P A SG 11202002636PA SG 11202002636P A SG11202002636P A SG 11202002636PA SG 11202002636P A SG11202002636P A SG 11202002636PA
- Authority
- SG
- Singapore
- Prior art keywords
- cell receptors
- receptors recognizing
- recognizing mutated
- mutated
- cell
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464448—Regulators of development
- A61K39/46445—Apoptosis related proteins, e.g. survivin or livin
- A61K39/464451—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762565383P | 2017-09-29 | 2017-09-29 | |
| PCT/US2018/051285 WO2019067243A1 (en) | 2017-09-29 | 2018-09-17 | T CELL RECEPTORS RECOGNIZING P53 MUTE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002636PA true SG11202002636PA (en) | 2020-04-29 |
Family
ID=63714167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002636PA SG11202002636PA (en) | 2017-09-29 | 2018-09-17 | T cell receptors recognizing mutated p53 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11939365B2 (es) |
| EP (1) | EP3688027A1 (es) |
| JP (2) | JP7324193B2 (es) |
| KR (1) | KR20200064110A (es) |
| CN (1) | CN111386282B (es) |
| AU (1) | AU2018342246B2 (es) |
| BR (1) | BR112020006012A2 (es) |
| CA (1) | CA3077024A1 (es) |
| CR (1) | CR20200170A (es) |
| EA (1) | EA202090757A1 (es) |
| IL (1) | IL273515A (es) |
| MA (1) | MA50651A (es) |
| MX (4) | MX2020003504A (es) |
| SG (1) | SG11202002636PA (es) |
| WO (1) | WO2019067243A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102375218B1 (ko) | 2016-12-08 | 2022-03-17 | 이매틱스 바이오테크놀로지스 게엠베하 | T 세포 수용체 및 이를 사용하는 면역 요법 |
| WO2020237368A1 (en) * | 2019-05-27 | 2020-12-03 | Provincial Health Services Authority | Immunotherapy constructs targeting kras antigens |
| US20220332785A1 (en) * | 2019-06-27 | 2022-10-20 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | T cell receptors recognizing r175h or y220c mutation in p53 |
| CN113512124A (zh) * | 2020-04-10 | 2021-10-19 | 香雪生命科学技术（广东）有限公司 | 一种识别hpv16的高亲和力tcr |
| WO2022051449A2 (en) * | 2020-09-04 | 2022-03-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing r273c or y220c mutations in p53 |
| WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| KR20240016288A (ko) * | 2021-05-07 | 2024-02-06 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | P53의 c135y, r175h 또는 m237i 돌연변이를 인식하는 t 세포 수용체 |
| WO2023050063A1 (zh) * | 2021-09-28 | 2023-04-06 | 溧阳瑅赛生物医药有限公司 | 一种识别hla-a*02:01/e629-38的tcr及其应用 |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
| WO2023215370A2 (en) * | 2022-05-04 | 2023-11-09 | University Of Massachusetts | Oligonucleotides for pms2 modulation |
| CN116063577A (zh) * | 2022-11-18 | 2023-05-05 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770749B2 (en) | 2000-02-22 | 2004-08-03 | City Of Hope | P53-specific T cell receptor for adoptive immunotherapy |
| US7456263B2 (en) * | 2001-06-05 | 2008-11-25 | Altor Bioscience Corporation | P53 binding T cell receptor molecules |
| WO2004021995A2 (en) | 2002-09-06 | 2004-03-18 | The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| JP6554099B2 (ja) * | 2013-08-07 | 2019-07-31 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． | ｐ５３変異体を再活性化することの可能なペプチド |
| EP3105335B1 (en) * | 2014-02-14 | 2019-10-02 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors and methods of making |
| AU2015249655B2 (en) * | 2014-04-23 | 2021-01-07 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (CAR) for use in therapy and methods for making the same |
| IL290655B2 (en) | 2014-05-29 | 2024-05-01 | Us Health | Anti-human papillomavirus 16 E7 T-cell chelates |
| AU2014407540C1 (en) | 2014-10-02 | 2021-07-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cells having antigenic specificity for a cancer-specific mutation |
| WO2016053338A1 (en) * | 2014-10-02 | 2016-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation |
| US20180045727A1 (en) | 2015-03-03 | 2018-02-15 | Caris Mpi, Inc. | Molecular profiling for cancer |
| CA2984234C (en) * | 2015-05-01 | 2023-10-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
| RU2733754C2 (ru) | 2015-05-20 | 2020-10-06 | Те Брод Инститьют Инк. | Общие неоантигены |
-
2018
- 2018-09-17 BR BR112020006012-7A patent/BR112020006012A2/pt unknown
- 2018-09-17 MA MA050651A patent/MA50651A/fr unknown
- 2018-09-17 CN CN201880074539.8A patent/CN111386282B/zh active Active
- 2018-09-17 SG SG11202002636PA patent/SG11202002636PA/en unknown
- 2018-09-17 MX MX2020003504A patent/MX2020003504A/es unknown
- 2018-09-17 EA EA202090757A patent/EA202090757A1/ru unknown
- 2018-09-17 KR KR1020207012344A patent/KR20200064110A/ko not_active Application Discontinuation
- 2018-09-17 EP EP18780006.5A patent/EP3688027A1/en active Pending
- 2018-09-17 CR CR20200170A patent/CR20200170A/es unknown
- 2018-09-17 WO PCT/US2018/051285 patent/WO2019067243A1/en active Application Filing
- 2018-09-17 JP JP2020517556A patent/JP7324193B2/ja active Active
- 2018-09-17 CA CA3077024A patent/CA3077024A1/en active Pending
- 2018-09-17 US US16/651,242 patent/US11939365B2/en active Active
- 2018-09-17 AU AU2018342246A patent/AU2018342246B2/en active Active
-
2020
- 2020-03-23 IL IL273515A patent/IL273515A/en unknown
- 2020-07-13 MX MX2024005676A patent/MX2024005676A/es unknown
- 2020-07-13 MX MX2024005678A patent/MX2024005678A/es unknown
- 2020-07-13 MX MX2024005677A patent/MX2024005677A/es unknown
-
2023
- 2023-07-28 JP JP2023123893A patent/JP2023159112A/ja active Pending
-
2024
- 2024-02-21 US US18/583,139 patent/US20240270814A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111386282A (zh) | 2020-07-07 |
| MX2024005677A (es) | 2024-06-11 |
| JP2021500010A (ja) | 2021-01-07 |
| CN111386282B (zh) | 2024-09-06 |
| EA202090757A1 (ru) | 2020-08-21 |
| MA50651A (fr) | 2020-08-05 |
| KR20200064110A (ko) | 2020-06-05 |
| IL273515A (en) | 2020-05-31 |
| CA3077024A1 (en) | 2019-04-04 |
| AU2018342246B2 (en) | 2024-08-08 |
| CR20200170A (es) | 2020-11-23 |
| BR112020006012A2 (pt) | 2020-10-06 |
| US20240270814A1 (en) | 2024-08-15 |
| MX2020003504A (es) | 2020-09-14 |
| MX2024005676A (es) | 2024-06-11 |
| EP3688027A1 (en) | 2020-08-05 |
| JP7324193B2 (ja) | 2023-08-09 |
| MX2024005678A (es) | 2024-06-11 |
| WO2019067243A1 (en) | 2019-04-04 |
| US11939365B2 (en) | 2024-03-26 |
| US20200277352A1 (en) | 2020-09-03 |
| JP2023159112A (ja) | 2023-10-31 |
| AU2018342246A1 (en) | 2020-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273515A (en) | T cell receptors that recognize mutated p53 | |
| IL271435A (en) | t cell receptors | |
| IL262144A (en) | t cell receptors | |
| IL262128A (en) | t cell receptors | |
| ZA201806862B (en) | T cell receptors | |
| ZA201806865B (en) | T cell receptors | |
| IL264425B1 (en) | t cell receptors against kras-g20 | |
| HK1257902A1 (zh) | 識別hla-cw8限制性突變kras的t細胞受體 | |
| RS64952B1 (sr) | T ćelijski receptori |